Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Exagen Inc. logo

NASDAQ · XGN

Exagen Inc.

Healthcare · Medical - Diagnostics & Research

$8.59

Down-$0.11 (-1.26%)

Updated Nov 1, 2026, 1:19 PM

SID Score

5.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
163.17M
P/E ratio
-8.94
Dividend yield
0.00%
52-week range
$2.59 – $9.22
Volume
394.01K
Avg. volume
318.13K

Price performance · XGN

XGN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

XGN closed at $8.59 after 20 trading sessions, up 1.54% for the selected period.

Last close
$8.59
Period change
+1.54%
Period low
$7.27
Period high
$8.70
Daily close
View OHLC price history
XGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$8.58$8.615$8.28$8.59394.01K
Oct 29, 2026$8.34$8.88$8.34$8.70378.38K
Oct 28, 2026$7.80$8.50$7.715$8.40348.82K
Oct 27, 2026$7.57$7.84$7.462$7.78180.71K
Oct 26, 2026$7.20$7.59$7.05$7.47191.38K
Oct 23, 2026$7.43$7.46$7.17$7.27222.79K
Oct 22, 2026$7.72$7.82$7.25$7.48219.16K
Oct 21, 2026$7.46$8.11$7.44$7.88285.82K
Oct 20, 2026$7.56$7.611$7.35$7.41425.29K
Oct 19, 2026$7.72$7.9999$7.39$7.43471.49K
Oct 16, 2026$8.46$8.55$7.30$7.72966.19K
Oct 15, 2026$8.34$8.63$8.17$8.56393.9K
Oct 14, 2026$8.35$9.22$8.32$8.42613.48K
Oct 13, 2026$8.18$8.66$8.13$8.48469.99K
Oct 12, 2026$8.20$8.4867$8.11$8.25201.4K
Oct 9, 2026$8.17$8.55$7.98$8.42251.15K
Oct 8, 2026$8.24$8.25$7.98$8.17362.59K
Oct 7, 2026$7.98$8.36$7.89$8.30235.26K
Oct 6, 2026$8.53$8.70$8.09$8.19272.07K
Oct 5, 2026$8.41$8.535$8.015$8.46291.76K

Latest XGN news

The latest Smart Investors Daily articles mentioning XGN.

Stock researchCompany · Overview

XGN research

Overview

Company profile and research snapshot.

Company profile

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.33
Implied upside
—
Analysts
—
XGN recent ratings
DateFirmRatingTarget
Oct 19, 2026Canaccord GenuityBuy—
Oct 13, 2026TD CowenBuy—
Aug 5, 2026BTIGBuy—
Aug 5, 2026B. Riley SecuritiesBuy—
Aug 5, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Exagen to Announce Third Quarter Financial Results on November 10, 2026

CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2026, before the market opens on Tuesday, November 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a webcast at 8:00 a.m. ET (5:00 a.m. PT) that morning to review the results. The webcast will be available on the Exagen Investor Relatio

Benzinga · Sep 17, 2026

Full Transcript: Exagen Q2 2026 Earnings Call

On Tuesday, Exagen (NASDAQ:XGN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By